A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Infections, Human Immunodeficiency Virus and Herpesviridae

Interventions

DRUG

GSK1265744 injectable suspension

200 milligram per milliliter sterile solution for injection

OTHER

Placebo to match injectable suspension

placebo